Annovis to Attend the CTAD 2026 with Three PresentationsGlobeNewsWire · 2 days ago
Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer's DiseaseGlobeNewsWire · Sep 23, 2026
Annovis Bio (ANVS) Loses 26.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research · Sep 8, 2026
Annovis Bio Targets March 2027 Alzheimer's Readout, Prepares Rolling NDAMarketBeat · Sep 2, 2026
Annovis to Host Corporate Update Webinar on September 2, 2026GlobeNewsWire · Aug 25, 2026
Annovis Provides Corporate Updates and Second Quarter 2026 Financial ResultsGlobeNewsWire · Aug 14, 2026Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 14, 2026 | -$0.45 | -$0.40 | Beat |
| May 15, 2026 | -$0.40 | -$0.63 | Miss |
| Mar 16, 2026 | -$0.31 | -$0.39 | Miss |
| Nov 12, 2025 | -$0.36 | -$0.37 | Miss |
| Aug 12, 2025 | -$0.36 | -$0.32 | Beat |
| May 13, 2025 | -$0.47 | -$0.32 | Beat |